COMPLEX ISSUES IN CORONARY REVASCULARIZATION: Edited by Bobby Yanagawa and Subodh VermaSodium–glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered careVerma, Subodha; Klug, Ericb; Mareev, Viacheslav Y.c; Kobalava, Zhanna D.d; Connelly, Kim A.e; Arici, Mustafaf; Berwanger, Otáviog; Santoso, Anwarh; Mehta, Roopai; Meglis, Gusj; Kosiborod, Mikhail N.k,lAuthor Information aDivision of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada bDivision of Cardiology, Charlotte Maxeke Johannesburg Academic Hospital, Netcare Sunninghill and Sunward Park Hospitals, Johannesburg, South Africa cLomonosov Moscow State University Medical Research and Educational Center, Moscow, Russia dDepartment of Internal Medicine and Cardiology, Peoples’ Friendship University of Russia (RUDN University), Moscow, Russia eDivision of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada fDepartment of Nephrology, Hacettepe University, Ankara, Turkey gHospital Israelita Albert Einstein (Academic Research Organization-ARO), São Paulo, Brazil hDepartment of Cardiology and Vascular Medicine, Universitas Indonesia, Harapan Kita National Cardiovascular Center – Harapan Kita Hospital, Jakarta, Indonesia iDepartment of Endocrinology and Metabolism, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico jMarlee Medical Centre, Toronto, Ontario, Canada kSaint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri, USA lThe George Institute for Global Health and University of New South Wales, Sydney, New South Wales, Australia Correspondence to Subodh Verma, MD, PhD, FRCSC, Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Suite 8-003, 30 Bond Street, Toronto, ON, Canada M5B 1W8. Tel: +1 416 864 5997; e-mail: [email protected] Current Opinion in Cardiology: September 2020 - Volume 35 - Issue 5 - p 589-601 doi: 10.1097/HCO.0000000000000774 Buy Metrics Abstract Purpose of review The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. Recent findings Sodium–glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes. Summary Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.